Cargando…
Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
Autores principales: | Yardley, Denise A., Noguchi, Shinzaburo, Pritchard, Kathleen I., Burris, Howard A., Baselga, José, Gnant, Michael, Hortobagyi, Gabriel N., Campone, Mario, Pistilli, Barbara, Piccart, Martine, Melichar, Bohuslav, Petrakova, Katarina, Arena, Francis P., Erdkamp, Frans, Harb, Wael A., Feng, Wentao, Cahana, Ayelet, Taran, Tetiana, Lebwohl, David, Rugo, Hope S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4713958/ http://dx.doi.org/10.1007/s12325-014-0150-8 |
Ejemplares similares
-
Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis
por: Yardley, Denise A., et al.
Publicado: (2013) -
Everolimus plus exemestane as first-line therapy in HR(+), HER2(−) advanced breast cancer in BOLERO-2
por: Beck, J. Thaddeus, et al.
Publicado: (2013) -
Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2()
por: Hortobagyi, Gabriel N.
Publicado: (2015) -
Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2
por: Rugo, H. S., et al.
Publicado: (2014) -
Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
por: Noguchi, Shinzaburo, et al.
Publicado: (2013)